Peptide-based angiogenesis inhibitors and methods of use...

Details Peptide-based angiogenesis inhibitors and methods of use... Peptide-based angiogenesis inhibitors and methods of use...

2006-10-24

2006-10-24

Chism, B. Dell (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S014800, C514S015800, C514S016700, C514S017400, C530S327000, C530S328000, C530S329000

Reexamination Certificate

active

07125849

ABSTRACT:
Angiogenesis inhibitors and methods of use thereof are disclosed. The inhibitors are substantially pure oligopeptides consisting essentially of 7–20 amino acid residues and comprising a proline-rich sequence of five amino acid residues PPXPP, SEQ ID NO: 1, wherein X is an amino acid residue selected from the group consisting of alanine, glycine, serine, threonine, valine, leucine and methionine. In a preferred embodiment, the proline-rich polypeptide is covalently bound to a transport molecule such as a Tat-derived transport polypeptide.

REFERENCES:
patent: 6660843 (2003-12-01), Feige et al.
Kiosses et al., Circulation Research 2002, vol. 90, pp. 697-702.
Kelly et al., Biochemistry 2001, Vo. 40, pp. 14376-14383.

Affiliated with

Also associated with

Rating

Peptide-based angiogenesis inhibitors and methods of use... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptide-based angiogenesis inhibitors and methods of use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide-based angiogenesis inhibitors and methods of use... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3668185